BIIB

$BIIB chatter on StockTwits

• 
  KSap@ksoptionBullish5h

  $NBIS $C $BIIB 🤞

  View on StockTwits ↗
• 
  Go for ProMIS@GoforProMISBullish16h

  $PMN PT Raised to $100 at Guggenheim Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drug's efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer's. If PMN shows the potential to be safer than existing treatments $LLY $BIIB. FDA views it ethical imperative to expedite the approval process through fast-track programs. https://www.streetinsider.com/dr/news.php?id=26925256&gfv=1

  View on StockTwits ↗
• 
  11th.com@11thestate17h

  There’s another $BIIB investor settlement to know about. The settlement centers on claims that Biogen misled investors about aducanumab’s clinical trial data and why the ENGAGE study failed. After FDA briefing materials raised concerns in 2020, the FDA Advisory Committee voted 10-0 against the drug’s effectiveness, and $BIIB fell 28%. This case covers purchases between 2019 and 2020. If you weren't eligible for the other Biogen case, you may want to check this one, since the class period is different and extends further back. Check if your eligible and file a claim: https://11th.com/cases/biogen-investor-settlement

  View on StockTwits ↗
• 
  vijay@vjtweetBullish2d

  $BIIB new long. No rush.. hold for many months.

  View on StockTwits ↗
• 
  11th.com@11thestate4d

  Imagine buying $BIIB at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $BIIB investors out there, we’ve got some important news: a $18.9 million investor settlement is now open for claims from shareholders who purchased shares in 2021 The deadline is next months, you can check if you’re eligible and claim your share: https://11th.com/cases/biib-investor-settlement

  View on StockTwits ↗
• 
  Fangster1@Fangster15d

  $BIIB $GANX $JAZZ Very good give and take to this thread. I’ll never pretend to fully understand the science but I do understand statements made by the company. IMO they have a good idea where the 270 stands. If the 270 is a known negative, I would think some level of disclosure would be necessary after the company speak. As an investor, no issue waiting for the 360. If the 360 plays out, we’re solid gold with diamond hands. We’ll see!

  View on StockTwits ↗
• 
  Jwa68@Jwa68Bullish6d

  $GANX Khalid and Gene are very wisely beginning to position Gain as a platform company, versus a single drug company, with a vast multi target franchise opportunity in neurodegeneration. With Magellan capable of generating an endless organic pipeline of additional molecules which may be advanced to the clinic, all building upon what they have learned from GT-00287. While we will never get there unfortunately, this is similar to how $BIIB (Biogen) was started way back when and trading at just a couple dollars a share, along with $JAZZ. Ironically, Gene was one of the first analysts to initiate and recommend both names in their infancy, early on on his career as an analyst.

  View on StockTwits ↗
• 
  Go for ProMIS@GoforProMISBullishAug 7

  $PMN $LLY $BIIB $RHHBY The real jackpot: PMN267 + PMN442 ProMIS describes three key antibody programs: PMN310 → Alzheimer's disease / Amyloid-ß oligomers => PMN310 potential $5-10 bn * PMN267 → ALS / misfolded TDP-43 => PMN267 potential $1-3 bn * PMN442 → Parkinson's disease, MSA, => PMN442 potential $1-3 bn and other synucleinopathies Other Platforms potential $0,5-2 bn means in total range from 7.5-18 bn with a potential Share price of => $405 to $970 This is not pure fantasy.

  View on StockTwits ↗
• 
  Robin Quinn@jewell69Aug 6

  8/6 2:01 pm edt re-entry $BIIB Biogen, Inc Status Filled at $205.504 Symbol BIIB Symbol Description BIOGEN INC COM USD0.0005 Action Buy Quantity 20 Shares

  View on StockTwits ↗
• 
  Minimalist Review@MarketIntel_Aug 5

  Today's Trading Watchlist $AVAV - Hold $170, targets $184 and $193. $AVGO - Trigger over $422, target $440. $BB - Trigger over $8.95, target $10. $BE - Trigger over $236, targets $254 and $268. $BIIB - Trigger over $209, target $216. Keeping these names on radar as price action decides the next move. Focus is on confirmation, not chasing.

  View on StockTwits ↗
• 
  Brenda Saxe@BrendaSaxe1022Aug 5

  $CFG $GFI $BIIB $RDDT $ILMN Citizens Financial strengthens banking operations, Gold Fields benefits from higher gold prices, Biogen advances neurological therapies, Reddit continues improving advertising monetization, and Illumina leads genomic sequencing.

  View on StockTwits ↗
• 
  Gabriel Barrett@GabrielBarrett973Aug 5

  $CNC $LVS $AEE $SUNB $BIIB Centene benefits from managed healthcare growth, Las Vegas Sands gains from casino demand, Ameren provides regulated utility exposure, SUNB remains execution-driven, and Biogen advances neurological therapies.

  View on StockTwits ↗
• 
  Y@jdlmanAug 4

  $INCY $BIIB ..shut up josh brown .. always says it after the fact

  View on StockTwits ↗
• 
  Quantumup@QuantumupAug 4

  Canaccord Genuity y'day⬇️ $STOK to $58 from $60 and reiterated Buy after STOK reported its 2Q26 results. $BIIB PRAX DRUG HLUBF HLBBF $IONS HRMY OVID SUPN UCBJY JAZZ Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2084604516561756445?s=20

  View on StockTwits ↗
• 
  Rob Lewis@IN0V8Aug 3

  $BIIB Citigroup raises target price to $215 from $200

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.